Madrigal Pharmaceuticals, Inc. (MDGL) NASDAQ
510.68
-8.08(-1.56%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
510.68
-8.08(-1.56%)
Currency In USD
Address
Four Tower Bridge
West Conshohocken, PA 19428
United States of America (the)
Phone
267 824 2827
Sector
Healthcare
Industry
Biotechnology
Employees
528
First IPO Date
February 06, 2007
| Name | Title | Pay | Year Born |
| William J. Sibold | Chief Executive Officer, President & Director | 1.85M | 1966 |
| Shannon Kelley | Executive VP, Chief Legal Officer & Corporate Secretary | 782,208 | 1975 |
| Carole Huntsman | Executive VP & Chief Commercial Officer | 870,825 | 1965 |
| Mardi C. Dier | Executive VP & CFO | 934,681 | 1964 |
| Rebecca A. Taub | Founder, Senior Scientific & Medical Advisor and Director | 1.07M | 1952 |
| Clint Wallace | Executive VP & Chief Human Resources Officer | 0 | N/A |
| Edward Chiang | Senior Vice President of Clinical & Technical Operations | 0 | N/A |
| Mark Underwood | Executive Vice President of Business Planning & Operations | 0 | N/A |
| Ronald Filippo | Executive VP & Chief Information Officer | 0 | N/A |
| Tina E. Ventura | Chief Investor Relations Officer | 0 | N/A |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.